Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant

Araf, Shamzah; Wang, Jun; Ashton‐Key, Margaret; Korfi, Koorosh; Bella, Doriana Di; Río-Machín, Ana; Odabashian, Mariette; Foria, Vipul; Du, Ming; Cucco, Francesco; Barrans, Sharon; Johnson, Peter; Laird, Sophie R.; Fisher, Andrew M.; Cullis, Jonathan O.; Graham, Trevor A.; Okosun, Jessica; Fitzgibbon, Jude; Chiecchio, Laura

doi:10.3324/haematol.2018.196907

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 22 , 34 The existence of such progenitor populations has been exemplified in two reports of clonally related FL and clonally related DLBCL arising in both donor and recipient after hematopoietic stem cell transplantation. 35 , 36 In both studies, the related lymphomas exhibited multiple shared alterations, which were therefore acquired prior to transplantation. 35 , 36 Likewise, FL and transformed FL have been shown to often arise by divergent evolution.…”

Section: Discussionmentioning

confidence: 99%

“… 35 , 36 In both studies, the related lymphomas exhibited multiple shared alterations, which were therefore acquired prior to transplantation. 35 , 36 Likewise, FL and transformed FL have been shown to often arise by divergent evolution. 37 , 38 The complexity of this evolutionary process is also reflected in our paired ISFN and aggressive BCL cases, since the distribution of private and shared mutations suggests an early subclonal divergence for the majority of cases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

et al. 2020

View full text Add to dashboard Cite

In situ follicular neoplasia (ISFN) is the earliest morphologically identifiable precursor of follicular lymphoma (FL). Although it is genetically less complex than FL and has low risk for progression, ISFN already harbors secondary genetic alterations, in addition to the defining t(14;18)(q32;q21) translocation. FL, in turn, frequently progresses to diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). By BCL2 staining of available reactive lymphoid tissue obtained at any time point in patients with aggressive B-cell lymphoma (BCL), we identified ten paired cases of ISFN and DLBCL/HGBL, including six de novo tumors and four tumors transformed from FL as an intermediate step, and investigated their clonal evolution using microdissection and next-generation sequencing. A clonal relationship between ISFN and aggressive BCL was established by immunoglobulin and/or BCL2 rearrangements and/or the demonstration of shared somatic mutations for all ten cases. Targeted sequencing revealed CREBBP, KMT2D, EZH2, TNFRSF14 and BCL2 as the genes most frequently mutated already in ISFN. Based on the distribution of private and shared mutations, two patterns of clonal evolution were evident. In most cases, the aggressive lymphoma, ISFN and, when present, FL revealed divergent evolution from a common progenitor, whereas linear evolution with sequential accumulation of mutations was less frequent. In conclusion, we demonstrate for the first time that t(14;18)+ aggressive BCL can arise from ISFN without clinically evident FL as an intermediate step and that during this progression, branched evolution is common.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, stem cell science is a relatively new science, and therapeutic development using stem cells, even approved stem cell therapies for blood diseases, is in need of a better understanding of mechanisms of action and acute and long-term safety profiles, both for the cells and their released molecules. Approved bone marrow stem cell (BMSC) transplants have many associated risks, including possible induction of cancer [ 8 ], including skin cancer [ 9 ], the transference of cancer cells from the donor to the patient [ 10 ] – given the bone marrow is a site of recirculated cancer cells [ 11 , 12 ] – transference and engraftment of BMSCs with pathogenic mutations [ 13 ], and aging of the tissue in which the implant occurs [ 14 ]. Many factors, which are often overlooked, must be considered when developing stem cell-based therapeutics, including something as fundamental as the choice of stem cell type where adipose mesenchymal stem cells (ADSCs) have many advantages over BMSCs for therapeutic development [ 15 ].…”

mentioning

confidence: 99%

The Safety of a Therapeutic Product Composed of a Combination of Stem Cell Released Molecules From Adipose Mesenchymal Stem Cells and Fibroblasts

Maguire¹,

Friedman²

2020

Future Sci. OA

View full text Add to dashboard Cite

Aim: We sought to determine the safety profile of a therapeutic candidate composed of the released molecules from a combination of human adipose-derived mesenchymal stem cells and fibroblasts. Although stem cells, their progenitor cells and the molecules that are released from these cells have some demonstrated therapeutic value, much more needs to learn about the efficacy, mechanism of action and the safety profiles of these stem cell-based therapeutics. Methods: A number of cellular, in vitro, in vivo and human studies were performed to analyze cellular, tissue and systemic safety profiles of the combinatorial product. Results: At the levels tested in this study, ranging from demonstrated therapeutic doses to supratherapeutic doses, the combinatorial product demonstrated an excellent safety profile in all in vitro, cellular, tissue and systemic studies. Conclusions: We found evidence that a therapeutic candidate composed of the molecules released from human adipose-derived mesenchymal stem cells and human fibroblasts has an excellent safety profile, and that the product warrants further studies for safety and efficacy where dosing may include topical application, injection and oral application.

show abstract

Benefits of serum protein electrophoresis as part of hematopoietic stem cell donor clearance

Kilinc,

Schleipen,

Ende

et al. 2024

eJHaem

View full text Add to dashboard Cite

Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant

Cited by 5 publications

References 15 publications

Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

The Safety of a Therapeutic Product Composed of a Combination of Stem Cell Released Molecules From Adipose Mesenchymal Stem Cells and Fibroblasts

Benefits of serum protein electrophoresis as part of hematopoietic stem cell donor clearance

Contact Info

Product

Resources

About